Ken B. Hanscombe

Ken B. Hanscombe

Auto-generated profile, based on publicly available information

Ken B. Hanscombe

King's College London

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2021 in Genome Medicine
Verified
Journal Article
Open access
PDF file
KHKen B. Hanscombe
Ken B. Hanscombe
EPElodie Persyn
Elodie Persyn
MTMatthew Traylor
Matthew Traylor
KGKylie P. Glanville
Kylie P. Glanville
MHMark Hamer
Mark Hamer
CLCathryn Lewis
Cathryn Lewis
Background: Cardiorespiratory fitness (CRF) and physical activity (PA) are well-established predictors of morbidity and all-cause mortality. However, CRF is not routinely measured and PA not routinely prescribed as part of standard healthcare. The American Heart Association (AHA) recently presented a scientific case for the inclusion of CRF as a clinical vital sign based on epidemiological and clinical observation. Here, we leverage genetic data in the UK Biobank (UKB) to strengthen the case for CRF as a vital sign and make a case for the prescription of PA.Methods: We derived two CRF measures from the heart rate data collected during a submaximal cycle ramp test: CRF-vo2max, an estimate of the participants' maximum volume of oxygen uptake, per kilogram of body weight, per minute; and CRF-slope, an estimate of the rate of increase of heart rate during exercise. Average PA over a 7-day period was derived from a wrist-worn activity tracker. After quality control, 70,783 participants had data on the two derived CRF measures, and 89,683 had PA data. We performed genome-wide association study (GWAS) analyses by sex, and post-GWAS techniques to understand genetic architecture of the traits and prioritise functional genes for follow-up.Results: We found strong evidence that genetic variants associated with CRF and PA influenced genetic expression in a relatively small set of genes in the heart, artery, lung, skeletal muscle and adipose tissue. These functionally relevant genes were enriched among genes known to be associated with coronary artery disease (CAD), type 2 diabetes (T2D) and Alzheimer’s disease (three of the top 10 causes of death in high-income countries) as well as Parkinson’s disease, pulmonary fibrosis, and blood pressure, heart rate, and respiratory phenotypes. Genetic variation associated with lower CRF and PA was also correlated with several disease risk factors (including greater body mass index, body fat and multiple obesity phenotypes); a typical T2D profile (including higher insulin resistance, higher fasting glucose, impaired beta-cell function, hyperglycaemia, hypertriglyceridemia); increased risk for CAD and T2D; and a shorter lifespan.Conclusions: Genetics supports three decades of evidence for the inclusion of CRF as a clinical vital sign. Given the genetic, clinical and epidemiological evidence linking CRF and PA to increased morbidity and mortality, regular measurement of CRF as a marker of health and routine prescription of PA could be a prudent strategy to support public health.

31 May 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KHKen B. Hanscombe
Ken B. Hanscombe
Jonathan ColemanJonathan Coleman
Jonathan Coleman
MTMatthew Traylor
Matthew Traylor
CLCathryn Lewis
Cathryn Lewis
The UK Biobank (UKB) is a resource that includes detailed health-related data on about 500,000 individuals and is available to the research community. However, several obstacles limit immediate analysis of the data: data files vary in format, may be very large, and have numerical codes for column names. ukbtools removes all the upfront data wrangling required to get a single dataset for statistical analysis. All associated data files are merged into a single dataset with descriptive column names. The package also provides tools to assist in quality control by exploring the primary demographics of subsets of participants; query of disease diagnoses for one or more individuals, and estimating disease frequency relative to a reference variable; and to retrieve genetic metadata. Having a dataset with meaningful variable names, a set of UKB-specific exploratory data analysis tools, disease query functions, and a set of helper functions to explore and write genetic metadata to file, will rapidly enable UKB users to undertake their research.

1 March 2020 in Biological Psychiatry
Verified
Journal Article
Open access
KGKylie P Glanville
Kylie P Glanville
Jonathan ColemanJonathan Coleman
Jonathan Coleman
KHKen B Hanscombe
Ken B Hanscombe
JEJack Euesden
Jack Euesden
SCShing Wan Choi
Shing Wan Choi
CLCathryn Lewis
Cathryn Lewis
The prevalence of depression is higher in individuals with autoimmune diseases, but the mechanisms underlying the observed comorbidities are unknown. Shared genetic etiology is a plausible explanation for the overlap, and in this study we tested whether genetic variation in the major histocompatibility complex (MHC), which is associated with risk for autoimmune diseases, is also associated with risk for depression. We fine-mapped the classical MHC (chr6: 29.6-33.1 Mb), imputing 216 human leukocyte antigen (HLA) alleles and 4 complement component 4 (C4) haplotypes in studies from the Psychiatric Genomics Consortium Major Depressive Disorder Working Group and the UK Biobank. The total sample size was 45,149 depression cases and 86,698 controls. We tested for association between depression status and imputed MHC variants, applying both a region-wide significance threshold (3.9 × 10-6) and a candidate threshold (1.6 × 10-4). No HLA alleles or C4 haplotypes were associated with depression at the region-wide threshold. HLA-B*08:01 was associated with modest protection for depression at the candidate threshold for testing in HLA genes in the meta-analysis (odds ratio = 0.98, 95% confidence interval = 0.97-0.99). We found no evidence that an increased risk for depression was conferred by HLA alleles, which play a major role in the genetic susceptibility to autoimmune diseases, or C4 haplotypes, which are strongly associated with schizophrenia. These results suggest that any HLA or C4 variants associated with depression either are rare or have very modest effect sizes.


26 August 2020 in medRxiv
Verified
Preprint
Open access
PDF file
CFChiara Fabbri
Chiara Fabbri
SHSaskia P. Hagenaars
Saskia P. Hagenaars
CJCatherine John
Catherine John
AWAlexander T. Williams
Alexander T. Williams
NSNick Shrine
Nick Shrine
CLCathryn Lewis
Cathryn Lewis
Treatment-resistant depression (TRD) is a major contributor to the disability caused by major depressive disorder (MDD). Using primary care electronic health records from UK Biobank and EXCEED studies, we defined MDD and TRD, providing an easily accessible approach to investigate their clinical and genetic characteristics. MDD defined from primary care records was compared with other measures of depression and validated using the MDD polygenic risk score (PRS). Using prescribing records, TRD was defined from at least two switches between antidepressant drugs, each prescribed for at least six weeks. Clinical-demographic characteristics, SNP-heritability and genetic overlap with psychiatric and non-psychiatric traits were compared in TRD and non-TRD MDD cases. In 230,096 and 8,926 UKB and EXCEED participants with primary care data, respectively, the prevalence of MDD was 8.7% and 14.2%, of which 13.2% and 13.5% was TRD (2,430 and 159 cases), respectively. In both cohorts, MDD defined from primary care records was strongly associated with MDD PRS, and in UKB it showed overlap of 72%-88% with other MDD definitions. In UKB, TRD and non-TRD heritability was comparable (h 2 SNP = 0.25 [SE=0.04] and 0.19 [SE=0.02], respectively). TRD was positively associated with the polygenic risk score (PRS) of attention deficit hyperactivity disorder and negatively associated with the PRS of intelligence compared to non-TRD. It was more strongly associated with unfavourable clinical-demographic variables than non-TRD. This study demonstrated that MDD and TRD can be reliably defined using primary care records and provides the first large scale population assessment of the genetic, clinical and demographic characteristics of TRD.

19 April 2022 in Genetic Epidemiology
Verified
Journal Article
Open access
AGAlexandra C. Gillett
Alexandra C. Gillett
BJBradley S. Jermy
Bradley S. Jermy
SLS. Hong Lee
S. Hong Lee
OPOliver Pain
Oliver Pain
DHDavid M. Howard
David M. Howard
CLCathryn Lewis
Cathryn Lewis
Substantial advances have been made in identifying genetic contributions to depression, but little is known about how the effect of genes can be modulated by the environment, creating a gene–environment interaction. Using multivariate reaction norm models (MRNMs) within the UK Biobank (N = 61294–91644), we investigate whether the polygenic and residual variance components of depressive symptoms are modulated by 17 a priori selected covariate traits—12 environmental variables and 5 biomarkers. MRNMs, a mixed‐effects modelling approach, provide unbiased polygenic–covariate interaction estimates for a quantitative trait by controlling for outcome‐covariate correlations and residual–covariate interactions. A continuous depressive symptom variable was the outcome in 17 MRNMs—one for each covariate trait. Each MRNM had a fixed‐effects model (fixed effects included the covariate trait, demographic variables, and principal components) and a random effects model (where polygenic–covariate and residual–covariate interactions are modelled). Of the 17 selected covariates, 11 significantly modulate deviations in depressive symptoms through the modelled interactions, but no single interaction explains a large proportion of phenotypic variation. Results are dominated by residual–covariate interactions, suggesting that covariate traits (including neuroticism, childhood trauma, and BMI) typically interact with unmodelled variables, rather than a genome‐wide polygenic component, to influence depressive symptoms. Only average sleep duration has a polygenic–covariate interaction explaining a demonstrably nonzero proportion of the variability in depressive symptoms. This effect is small, accounting for only 1.22% (95% confidence interval: [0.54, 1.89]) of variation. The presence of an interaction highlights a specific focus for intervention, but the negative results here indicate a limited contribution from polygenic–environment interactions.